Revista de la Asociación Latinoamericana de Diabetes
Guías ALAD de diagnóstico control y tratamiento de la Diabetes Mellitus Tipo 2.
  Principales referencias bibliográficas
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | página siguiente » ver pdf
 
  1. Abbasi F, Kamath V, Rizvi AA, et al. Results of a  Placebo-Controlled Study of the Metabolic Effects  of the Addition of Metformin to Sulfonylurea-Treated  Patients. Diabetes Care 1997; 20: 1863-1869   
     
  2. Abraira C, Colwell JA, Nuttall FQ et al: Veteran  affairs cooperative study on glycemic control and  complications in type 2 diabetes (VA CSDM): result  of the feasibility trial. Diab Care 1995; 18:1113-1123.   
     
  3. Abraira C, Henderson WG, Colwel JA, et al.  Response to Intensive Therapy Steps and to  Glipizide Dose in Combination with Insulin in Type 2  Diabetes. Diabetes Care 1998 ; 21 : 574 - 579   
     
  4. ADA: Report of the expert committee on the diagnosis  and clasification of diabetes mellitus. Diab Care  1998;21(suppl1) S5-S19.   
     
  5. Agardh CD, Garcia-Puig J, Carbonnel B,  Angelkort B and Barnett AH: Greater reduction of  urinary albumin excretion in hypertensive type II diabetic  patients with incipient nephropathy by lisinopril  than by nifedipine. J Human Hypert 1996;  10:185-192.   
     
  6. Akanuma Y, Kosaka K, Kanazawa Y, et al. Long  Term Comparison of oral Hypoglycemic agents in  diabetic retinopathy. Gliclazide vs. other sulfonylureas.  Diab Res Clin Pract 1988; 5: 81 - 90   
     
  7. Aljabri K, Kozak S, Thompson D et al.: Addition of  Pioglitazone or Bedtime Insulin to Maximal Doses of  Sulfonylurea and Metformin in Type 2 Diabetes  Patients with Poor Glucose Control: A Prospective,  Randomized Trial. Amm J Med. 2004; 116: 230-235.   
     
  8. American Diabetes Association. Consensus  Development Conference on Diabetic Foot Wound  Care. Diabetes care 1999; 22:1354-1360   
     
  9. Anderson JH, Brunelle RL, Keohane P et al: mealtime  treatment with insulin analog improves postprandial  hyperglycemia and hypoglycemia in  patients with non-insulin-dependent diabetes mellitus.  Arch Intern Med 1997;157:1249-1255.   
     
  10. Apfel SC, Kessler JA, Adornato BT et al:  Recombinant human nerve growth factor in the treatment  of diabetic polineuropathy. Neurology 1998;  51:695-702.   
     
  11. Aschner P, de Sereday M: El creciente papel que  desempeña el Grupo Latinoamericano de  Epidemiología de la Diabetes (GLED). IDF Bulletin  1997;42:14-17.   
     
  12. Aschner P, Kattah W: Effects of the combination of  insulin and gliclazide compared with insulin alone in  type 2 diabetic patients with secondary failure to  oral hypoglycemic agents. Diab Res Clin Pract 1992;  18:23-30.   
     
  13. Ashcroft FM, Gribble FM: ATP-sensitive K channels  and insulin secretion: their role in health and disease.  Diabetologia 1999;42:903-919.   
     
  14. Backonja M, Beydoun A, Edwards KR et al:  Gabapentin for the symptomatic treatment of painful  neuropathy in patients with diabetes mellitus: a randomized  controllled trial. JAMA 1998; 280:1831-  1836.   
     
  15. Bakris GL, Copley JB, Vicknair N, Sadler R and  Leurgans S: Calcium channel blockers versus other  antihypertensive therapies on progression of NIDDM  associated nephropathy. Kidney Int 1996; 50: 1641-  50.   
     
  16. Bakris GL, Weir MR, DeQuattro V, McMahon FG:  Effects of an ACE inhibitor/calcium antagonist combination  on proteinuria in diabetic nephropathy.  Kidney Int 1998; 54:1283-1289.   
     
  17. Bantle JP, Swanson JE, Thomas W, Laine DC:  Metabolic effects of dietary sucrose in type II diabetic  subjects. Diab Care 1993; 16:1301-1305.   
     
  18. Bauer J, Reams G, Hewett J, Klachko D et al: A  randomized, double-blind, placebo-controlled trial  to evaluate the effect of enalapril in patients with clinical  diabetic nephropathy. Am J Kidney Dis 1992;  20:443-457.   
     
  19. Bayraktar M, Thiel D, Nezaket A: A Comparison of  Acarbose Versus Metformin as an Individual Therapy  in Sulfonylurea-Treated NIDDM Patients. Diabetes  Care, 1996; 19:252-254   
     
  20. Benedetti M, Humburg E, Dressler A et al.: A Oneyear,  Randomised, Multicentre Trial Comparing  Insulin Glargine with NPH Insulin in Combiation with  Oral Agents in patients with Type 2 Diabetes 2003;  Horm Metab Res 2003; 35(3): 189-196.   
     
  21. Bennett A, Nicolucci A, Williams R: The efficacy of  aldose reductase inhibitors in the treatment of diabetic  peripheral neuropathy: a systematic review.  The Cochrane Library 1999.4   
     
  22. Berne C. On behalf of Orlistat Swedish Type 2  diabetes Study Group. A randomized study of orlistat  in combination with a weight management programme  in obese patients with Type 2 diabetes  treated with metformina. Diabet. Med 2005; 22: 612-  618.   
     
  23. Björk S, Jhonsen SA, Nyberg G, Aurell M:  Contrasting effects of enalapril and metoprolol on  proteinuria in diabetic nephropathy. BMJ 1990; 300:  904-07.   
     
  24. Bloomfield H, Robins SJ, Collins D et al:  Gemfibrozil for the secondary prevention of coronary  heart disease in men with low levels of high-density  lipoprotein cholesterol. New Engl J Med 1999;  341:410-418.   
     
  25. Brown SA, Upchurch S, Anding R, et al: Promoting  weight loss in type II diabetes. Diab Care  1996;19:613-623.   
     
  26. Brown SA: Studies of educational intervention and  outcomes in diabetic adults: a meta-analisis revisited.  Pat Educ Couns 1990;16:189-215.   
     
  27. Campbell IW and Howlett HCS. Worldwide  Experience of Metformin as an effective Glucose-lowering Agent: A Meta-analysis. Diabetes/  Metabolism Reviews 1995; 11: S57-S62
subir 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | página siguiente »
  Otros artículos de este número
Editorial
 Dra. Gloria Lopez
 
Guías ALAD de diagnóstico control y tratamiento de la Diabetes Mellitus Tipo 2.
 Capítulo 9. Complicaciones agudas severas de la DM2 
 Capítulo 10. Complicaciones oftalmológicas 
 Capítulo 11. Complicaciones renales 
 Capítulo 12. Complicaciones neurológicas 
 Capítulo 13. Pie diabético 
 Capítulo 14. Hipertensión arterial 
 Capítulo 15. Dislipidemias 
 Capítulo 16. Diabetes y Enfermedad Coronaria 
 Anexo 1. Conceptos básicos sobre medicina basada en evidencia 
 Anexo 2. Números necesarios por tratar para prevenir eventos con diversas intervenciones en personas con DM2 
  
Asociación Latinoamericana de Diabetes